IPP Bureau
Eris Lifesciences posts consolidated Q4FY23 PAT at Rs. 65.41 Cr
By IPP Bureau - May 22, 2023
Eris Lifesciences has reported total income of Rs. 403.80 crores during the period ended March 31, 2023
Zydus Wellness' FY23 consolidated net sales up 12.8% at Rs. 2243 Cr
By IPP Bureau - May 22, 2023
Glucon-D, Sugar Free, EverYuth Scrub, Peel Off Face Mask and Nycil maintained their leadership positions in their respective categories as on March 2023
GlaxoSmithKline Pharmaceuticals posts consolidated Q4 FY2023 PAT at Rs. 133.43 Cr
By IPP Bureau - May 22, 2023
The company has reported total income of Rs. 815.11 crores during the period ended March 31, 2023
Mandaviya to inaugurate conference on 'India Pharma & India Medical Devices’ on May 26-27
By IPP Bureau - May 22, 2023
8th Edition of the event to promote India as a manufacturing hub of quality medical products in the Pharmaceutical and Medical Devices Sector
Modi addresses 76th session of the World Health Assembly in Geneva virtually
By IPP Bureau - May 22, 2023
India’s efforts are aimed at boosting health at the last mile
Croda signs supply deals with Amyris, BSI for vaccine adjuvants
By IPP Bureau - May 21, 2023
These announcements are in line with Croda Pharma’s strategy to “Empower Biologics Delivery” and follows news on investments, earlier this year, to expand Croda Pharma’s global manufacturing capabilities to enable the next generation vaccines and therapeutic drugs.
Abbott India posts Q4FY23 PAT at Rs. 231.42 Cr
By IPP Bureau - May 20, 2023
The company has reported total income of Rs. 1392.72 crores during the period ended March 31, 2023
Alkem Laboratories posts Q4 FY23 consolidated PAT slides to Rs. 70.98 Cr
By IPP Bureau - May 20, 2023
The company has reported total income of Rs. 2971.27 crores during the period ended March 31, 2023
Strides Puducherry facility receives EIR from USFDA
By IPP Bureau - May 20, 2023
The USFDA had classified Strides Puducherry facility as OAI in May 2019 followed by issuing a warning letter to this site in July 2019.
Granules India received ANDA approval for Venlafaxine ER capsules
By IPP Bureau - May 20, 2023
Venlafaxine HCl extended-release capsules are indicated for the treatment of: Major Depressive Disorder
Moderna presents Phase 1/2 of MRNA-3927at 2023 ASGCT Meeting
By IPP Bureau - May 20, 2023
First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement
Venus Remedies recognized for R&D excellence by DSIR
By IPP Bureau - May 19, 2023
Leading Research-driven Pharma Company Combats Antibiotic Resistance and Demonstrates Innovation in Medical Solutions
Thermo Fisher Scientific expands ImmunoCAP test availability across U.S.
By IPP Bureau - May 19, 2023
Testing supporting allergy diagnosis now accessible to more people in more communities
Takeda to strengthen health system for rare diseases in India
By IPP Bureau - May 19, 2023
These initiatives aim to improve access to healthcare for rare disease patients
KIMS posts Q4FY23 consolidated PAT at Rs. 93.27 Cr
By IPP Bureau - May 19, 2023
The company has reported total income of Rs. 580.81 crores during the period ended March 31, 2023
